Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dynavax Technologies Corporation (DVAX) Share Price
Media stories about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive on Monday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.8457089037963 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Wall Street Consensus Watch on Dynavax Technologies Corporation (NASDAQ:DVAX) – Evergreen Caller (evergreencaller.com)
- Dynavax: An Important FDA Update – Seeking Alpha (seekingalpha.com)
- Dynavax Technologies Corporation (DVAX) Upgraded at Zacks Investment Research (americanbankingnews.com)
- Chartists Placing Dynavax Technologies Corp (DVAX) on Their Radar – Evergreen Caller (evergreencaller.com)
- Is Dynavax Technologies Corporation (DVAX) a good buy? – ExpressNewsline (expressnewsline.com)
Several equities research analysts have recently commented on DVAX shares. Royal Bank Of Canada increased their price objective on Dynavax Technologies Corporation from $6.00 to $7.00 and gave the company a “sector perform” rating in a report on Tuesday, May 9th. ValuEngine downgraded Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research raised Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Monday, July 10th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and issued a $45.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Dynavax Technologies Corporation presently has an average rating of “Hold” and a consensus price target of $23.67.
Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 7.25% during midday trading on Monday, hitting $17.75. The stock had a trading volume of 2,518,207 shares. The stock’s 50-day moving average is $9.75 and its 200-day moving average is $6.44. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $17.80. The stock’s market capitalization is $882.18 million.
Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 101.98% and a negative net margin of 1,323.99%. During the same quarter in the previous year, the firm earned ($0.75) earnings per share. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.72) EPS for the current fiscal year.
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.